Compound
← Compound
Official website →
MRNAModerna, Inc.
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- MRNA
- Moeda das demonstrações
- USD
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditi…
IndustryBiotechnology
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
-19.3×
P/B
Price divided by book value
9.02×
EV/EBITDA
Enterprise value divided by operating cash generation
-21.45×
EV/Revenue
Enterprise value divided by revenue
27.24×
What the company earns
ROE
Return on shareholders’ equity
-39.2%
ROA
Return on all assets
-28.7%
Gross margin
What remains after product costs
-12.6%
Operating margin
What remains after operating the business
-149%
Net margin
How much of each revenue unit becomes profit
-141.4%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
0.19
Total debt
Sum of borrowings
$1.29B
Cash
Cash available to cover it
$1.72B
Current ratio
Short-term assets divided by short-term liabilities
2.29
Free cash flow
Cash left after investing
-$563M
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.9
Revenue growth
Compared with the same period a year earlier
2.1%
Dividend yield
Trailing 12-month distributions divided by price
0%
Market data provider figures for the latest published period. Informational, not investment advice.
What research firms say
Buy 8Hold 16Sell 5· 29 firms
Published targetsrange 880% from lowest to highest
25.00median 122.50 USD245.00
Recent revisions
Rothschild & CoNeutral → Sell
Argus ResearchHold → Buy
Wolfe ResearchUnderperform → Peer Perform
Research-firm survey compiled by StreetInsider, Benzinga, Pulse 2.0. This is not Compound analysis or investment advice — Compound does not issue price targets.
Financial statements(USD)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 19.26B | 6.85B | 3.24B | 1.94B |
| Custo dos produtos | -5.42B | -4.69B | -1.46B | -868M |
| Pesquisa e desenvolvimento | -3.3B | -4.85B | -4.54B | -3.13B |
| Resultado operacional | 9.42B |
News about MRNA
Seeking Alpha · 14 hours ago
Moderna rallies 12% to set new high
MarketWatch · 15 hours ago
Moderna will reveal the data for its mRNA cancer vaccine next month. Here’s why it matters.
Yahoo Finance · 19 hours ago
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Investing Brasil · 21 hours ago
Por que as ações da Moderna estão disparando hoje?
Brazil Journal · yesterday
Na ArtRio, contemporâneo gira e secundário segue seletivo
Follow MRNA and get agent analysis of what is moving the stock.
Open Compound